A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
A prospective, multi-center, randomized, controlled, blinded trial of subjects implanted with VNS Therapy. Active treatment and no stimulation control are randomized, at least two weeks after implantation and observed for 12-months.
After completing the 12 month endpoint in the RCT portion of the study, all RECOVER subjects will transition into the prospective, open-label, longitudinal portion of the study. Subjects in the control arm of RECOVER will be activated after completing the 12 month endpoint.
After completion of enrollment in the RCT portion or meeting of interim success criterion (whichever comes first), up to 5,800 new subjects may enroll directly into the open-label,prospective, longitudinal study. These subjects will participate in the study for approximately 5 years.
The study has been designed in accordance with The Centers for Medicare and Medicaid Services coverage with evidence development (CED) decision entitled "Decision Memo for Vagus Nerve Stimulation (VNS) for Treatment Resistant Depression (TRD) (CAG-00313R2).
Inclusion Criteria:
The patient must be in a major depressive disorder (MDD) episode for ≥ two years or have had at least four episodes of MDD, including the current episode.
The patient's depressive illness meets a minimum criterion of four prior failed treatments of adequate dose and duration as measured by a tool designed for this purpose.
The patient is experiencing a major depressive episode (MDE) as measured by a guideline recommended depression scale assessment tool on two visits, within a 45-day span prior to implantation of the VNS device.
Patients must maintain a stable medication regimen for at least four weeks before device implantation.
Exclusion Criteria:
Current or lifetime history of psychotic features in any MDE;
Current or lifetime history of schizophrenia or schizoaffective disorder;
Current or lifetime history of any other psychotic disorder;
Current or lifetime history of rapid cycling bipolar disorder;
Current secondary diagnosis of delirium, dementia, amnesia, or other cognitive disorder;
Current suicidal intent; or
Treatment with another investigational device or investigational drugs.
laura.yates@livanova.com281-228-7200
Birmingham, Alabama 35294, United States
candacegreen@uabmc.edu205-976-0068
South Bend, Indiana 46601, United States
Buffalo, New York 14215, United States
Syracuse, New York 13210, United States
Cary, North Carolina 27519, United States
Houston, Texas 77054, United States
Huntington, West Virginia 25701, United States
Morgantown, West Virginia 26506, United States
hsvpsychresearch@uabmc.edu256-551-4431
bshih@atpcr.com714-277-4472
melissa@kaizenbraincenter.com866-277-2659
zoe.durkin@med.usc.edu213-631-8487
alexismarie@kindresearchgroup.com561-499-6933
yohana@galizresearch.com305-805-0921
cpartin@flourishresearch.com904-209-0043
cbussey@vantagetrials.com727-510-9773
kkenworthyapg@gmail.com407-808-1875
novapsychiatryinc@gmail.com401-883-9303
813-251-1800
Kaitlyn.Turner@k2med.com813-800-5252
scquinn@emory.edu404-727-9228
lmccloud@augusta.edu706-721-7968
jenniferk@nbmedicine.com770-422-2846
linda_skaggs@rush.edu312-942-6597
freeda@baberresearchgroup.com630-272-4844
awhite.pma@gmail.com847-679-8000 ext. 12
Oowasoyo94@siumed.edu217-545-7321
jbonilla@kumc.edu913-945-9790
Bryce.lund1@sheppardpratt.org410-938-3126
cschuessler@mgh.harvard.edu617-643-7690
matarneh@earlytreatment.org734-834-8954
ipl@umn.edu952-525-4505
ipl@umn.edu952-525-4505
kfickert@precise-research.com601-420-5810
sinklercs@health.missouri.edu573-882-5688
mhaug@pcrc-stl.com636-244-3593
abrouk@wustl.edu314-362-5113
lludwig@alivation.com402-817-2236
ngilbert@hp-imhs.com603-880-9880
mrainka@dentinstitute.com716-250-2038
tjimenezknight@chsbuffalo.org716-862-2426
esha.talati@mssm.edu332-243-7053
lisa.cottone@manumind.com516-808-0888 ext. 2
anne-marie.duchemin@osumc.edu614-293-5517
bbhattacharya@charakcenter.com715-209-4321
Michelle-matukewicz@ouhsc.edu918-660-3118
sterranella@gminstitutes.com570-346-3686 ext. 172
zbabar@gminstitutes.com570-346-3686 ext. 311
Joanna.Zheng@Pennmedicine.upenn.edu215-746-3513
maddoxm@musc.edu843-876-5141
anna.guidry@hopeforyourbrain.com615-973-9243
tyler.wilson@austin.utexas.edu512-495-5566
tara.upchurch@austin.utexas.edu512-495-5566
Hila.abushsegev@utsouthwestern.edu214-648-0401
pm.thompson@ttuhsc.edu915-215-5850
cip.research@uth.tmc.edu713-486-2567
northpointe.research@gmail.com214-799-8277
801-587-3297
sarah.kwon@hsc.utah.edu(801) 829-7382
mhollen@carilionclinic.org540-527-4875
dldunner@comcast.net206-230-0330
recovervns@seattlentc.com206-467-6300
May110@marshall.edu304-691-1500
rstauffach@clinicaltrials.wisc.edu608-262-7722